Hyperthermic Intra-Abdominal Chemotherapy with Gemcitabine as an Adjuvant Locoregional Treatment After Radical Surgery in Pancreatic Cancer

Author Info

Esther Pilar García Santos David Padilla-Valverde Susana Sánchez-García M. Carmen Manzanares-Campillo Alejandro Puerto-Puerto Marta Rodríguez-Martínez Lucía González-López Jesús Martín-Fernández

Corresponding Author

Esther Pilar García Santos
Servicio de Cirugía General y del Aparato Digestivo, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain

A B S T R A C T

Purpose: The aim of our study is to present a series of patients in whom we have administered HIPEC therapy. Material and Methods: The treatment consists in performing cytoreductive surgery in patients diagnosed with potentially resectable pancreatic adenocarcinoma, together with the administration of HIPEC therapy with Gemcitabine. The dose of the drug is 120 mg/m2 for 30 minutes, followed by a conventional adjuvant treatment. Results: Five patients diagnosed with pancreatic adenocarcinoma have undergone surgery with a curative nature. There were no technical or hemodynamic complications during the procedure. Discussion: The use of HIPEC could achieve a decrease in the tumor progression of pancreatic cancer, improving the survival of the patient, and decreasing the recurrence of the disease. A larger number of patients will be necessary, as well as a long-term evaluation to assess the possible increase in survival in this group of patients.

Article Info

Article Type

Research Article

Publication history

Received: Thu 25, Jun 2020
Accepted: Wed 15, Jul 2020
Published: Tue 28, Jul 2020

Copyright

© 2023 Esther Pilar García Santos. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.SCR.2020.07.16